Parmax Pharma Current Share Price | Parmax Pharma Stock Screener
PARMAX
Pharmaceuticals
Parmax Pharma Current Stock Price Today
Live Share Price BSE
₹135.05
▲
1.30 (0.97%)
As of September 15, 2026, the live Parmax Pharma share price (BSE: PARMAX) is ₹135.05, up 0.97% from the previous close, with shares trading between ₹135.00 and ₹135.05 in today's trading session, and a 52-week range of ₹25.22–₹135.05.
Browse PARMAX balance sheet details to support your investment research.
Use the Parmax Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Parmax Pharma Market Cap
₹45.61 Cr.
PARMAX P/E Ratio (TTM)
-10.80
Parmax Pharma P/B Ratio
-6.55
EPS (TTM)
₹-11.12
Dividend Yield
-
Debt to Equity
-
PARMAX 52 Week High
₹135.05
Parmax Pharma 52 Week Low
₹25.22
Operating Margin
-26.00%
Profit Margin
-5.00%
PARMAX Revenue (TTM)
₹20.00
EBITDA
-
Net Income
₹-1.00
Total Assets
₹28.00
Total Equity
₹-6.00
Parmax Pharma Current Share Price Chart
Track the current Parmax Pharma share price and stock price with an interactive chart. Analyse PARMAX price trends, trading volume, historical performance, and volatility across different timeframes — the complete Parmax Pharma stock quote in one place.
Parmax Pharma Company Profile - Fundamental Screener
Screen Parmax Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for PARMAX shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE240T01014
Parmax Pharma Balance Sheet Screener
Screen PARMAX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 28 | 19 | 15 | 18 | 18 | 23 | 21 | 20 | 17 | 8 |
| Current Assets | 17 | 10 | 6 | 8 | 7 | 10 | 9 | 9 | 9 | 4 |
| Fixed Assets | 8 | 8 | 9 | 10 | 10 | 11 | 10 | 5 | 6 | 3 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 12 | 8 | 6 | 5 | 5 | 6 | 5 | 5 | 2 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | -6 | -2 | 0 | 6 | 6 | 6 | 5 | 5 | 5 | 5 |
| Share Capital | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | -11 | -6 | -4 | 1 | 2 | 1 | 1 | 0 | 0 | 0 |
Parmax Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Parmax Pharma income statement and profit fundamentals.
Analyze PARMAX quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Parmax Pharma share price evaluation.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20 | 12 | 28 | 11 | 16 | 18 | 26 | 21 | 12 | 12 | 0 | 0 |
| Expenses | 21 | 16 | 28 | 14 | 13 | 16 | 23 | 19 | 11 | 11 | 0 | 0 |
| EBITDA | 0 | -4 | 0 | -3 | 2 | 3 | 4 | 2 | 1 | 1 | 0 | 0 |
| Operating Profit % | -26.00% | -30.00% | 1.00% | -31.00% | 15.00% | 14.00% | 13.00% | 8.00% | 9.00% | 9.00% | 0.00% | 0.00% |
| Depreciation | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -3 | -6 | -2 | -6 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -1 | -6 | -2 | -6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS | -3.20 | -11.12 | -5.60 | -34.56 | -0.28 | 0.38 | 2.02 | 1.15 | 0.21 | 0.00 | -0.02 | -0.01 |
Parmax Pharma Cash Flow Screener - Liquidity Fundamentals
Screen PARMAX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -1 | 0 | 0 | 1 | 4 | 3 | 1 | 4 | -1 | 0 |
| Investing Activities | -1 | -2 | -1 | -2 | -3 | -2 | -3 | -4 | 0 | 0 |
| Financing Activities | 1 | 1 | 0 | -1 | 0 | 0 | 3 | 1 | 1 | 0 |
| Net Cash Flow | 0 | 0 | -1 | -2 | 1 | 0 | 1 | 1 | 0 | 0 |
Parmax Pharma Shareholding Pattern Screener
See Parmax Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Parmax Pharma promoter holding and ownership changes for PARMAX on TickJournal.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 56.25% | 63.10% | 63.08% | 63.09% | 63.10% | 63.10% | 63.12% | 62.90% |
| Other Holding | 12.95% | 6.09% | 6.12% | 6.11% | 6.10% | 6.10% | 6.08% | 6.29% |
| Shareholder Count | 2,273 | 2,388 | 2,393 | 2,399 | 2,377 | 2,356 | 2,334 | 2,246 |
Parmax Pharma Share Dividend Screener - Share Yield Analysis
Check Parmax Pharma dividend history with payout and yield data.
View Parmax Pharma dividend details including ex-dates and amounts for PARMAX stock.
Parmax Pharma Stock Index Membership
See which indices include Parmax Pharma stock.
Check PARMAX index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Parmax Pharma Market Events Screener - Corporate Actions
Get Parmax Pharma corporate actions including splits, bonuses, and buybacks.
Check Parmax Pharma stock events that may affect PARMAX share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 6.06% |
| 2026-07-02 | 2026-07-02 | Extraordinary General Meeting | NA | 74.22% |
| 2026-06-02 | 2026-06-02 | Quarterly Result Announcement | NA | 2.90% |
| 2026-05-27 | 2026-05-27 | Extraordinary General Meeting | NA | 26.25% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | -1.72% |
| 2025-11-17 | 2025-11-17 | Quarterly Result Announcement | NA | -1.84% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -3.64% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 2.12% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -1.09% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -5.75% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 4.73% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 11.04% |
Parmax Pharma Competitors Screener - Peer Comparison
Screen PARMAX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,547 | 37.28 | 61,674 | 12.69% | 11,565 | 34.94 |
| Divis Laboratories | 227,321 | 77.10 | 11,067 | 13.95% | 2,568 | 71.94 |
| Torrent Pharmaceuticals | 189,499 | 86.36 | 13,886 | 20.34% | 2,138 | 50.31 |
| Cipla | 115,772 | 34.42 | 29,045 | 2.24% | 3,870 | 44.50 |
| Zydus Life Science | 112,527 | 24.59 | 27,658 | 17.64% | 5,026 | 49.84 |
| Lupin | 101,611 | 18.61 | 29,039 | 26.75% | 5,356 | 34.85 |
| Mankind Pharma | 98,797 | 47.94 | 14,636 | 14.85% | 1,938 | 38.70 |
| Dr Reddys Laboratories | 98,324 | 31.25 | 35,059 | 3.90% | 4,158 | 46.88 |
| Laurus Labs | 98,297 | 89.15 | 6,868 | 22.01% | 890 | 64.41 |
| Aurobindo Pharma | 94,362 | 25.43 | 34,145 | 5.56% | 3,503 | 56.48 |
Parmax Pharma Company Announcements - News Screener
Screen PARMAX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Announcement under Regulation 30 (LODR)-Newspaper Publication | - | |
| 2026-09-19 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-19 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-17 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-17 | Results For Quarter Ended June 30 2026 | - |
| 2026-09-17 | Board Meeting Outcome for Approval Of Unaudited Financial Results For Quarter Ended 30.06.2026 | - |
| 2026-09-16 | Disclosures under Reg. 18(6) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-13 | Board Meeting Intimation for Approval Of Quarterly Financial Results For Quarter Ended June 30 2026 | - |
| 2026-07-29 | Updates on Open Offer | - |
| 2026-07-27 | Updates on Open Offer | - |
| 2026-07-27 | Updates on Open Offer | - |
| 2026-07-22 | Letter of Offer | - |
| 2026-07-16 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-03 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-07-02 | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association | - |
| 2026-07-02 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-07-02 | Shareholder Meeting / Postal Ballot-Outcome of EGM | - |
| 2026-06-29 | Closure of Trading Window | - |
| 2026-06-25 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-06-23 | Corrigendum To The Notice Of (2Nd/2026-27) Extraordinary General Meeting Of The Company | - |